RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) — RxSight, Inc. (Nasdaq:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase up to 267,857 additional shares. RxSight’s gross proceeds from the offering were $115.0 million, before deducting underwriting discounts and commissions and other offering expenses.